Drug intelligence / Profile preview

hyperoside

Development stage
Preclinical
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

Hyperoside is a naturally occurring flavonol glycoside, specifically the 3-O-galactoside of quercetin, with the molecular formula C21H20O12 and a molecular weight of 464.40 g/mol[4][6][8][11]. It is commonly extracted from various fruits, vegetables, and medicinal plants, and is known for its wide spectrum of biological activities, including antioxidant, anti-inflammatory, antitumor, neuroprotective, vasoprotective, and hepatoprotective effects[1][3][5][7]. Mechanistically, hyperoside exerts its effects by modulating multiple cellular signaling pathways, such as PI3K/AKT, MAPK, AMPK, NF-κB, Wnt/β-catenin, and TLR4[1][3][9]. It induces apoptosis, inhibits cell proliferation, blocks angiogenesis, and sensitizes cancer cells to chemotherapy[1][3]. Hyperoside has demonstrated therapeutic potential in preclinical models for cancer, diabetes, Alzheimer’s disease, Parkinson’s disease, pulmonary fibrosis, and liver diseases[1][3][5][7]. It is not approved as a pharmaceutical drug; it is primarily experimented with in laboratory and preclinical models.

Other names
quercetin-3-O-galactosidequercetin3-O-galactosidequercetin 3-O-galactosidequercetin 3-O-β-D-galactopyranosidequercetin-3-galactosidequercetin3-galactosidequercetin 3-galactosidequercetin-3-D-galactosidequercetin3-D-galactosidequercetin 3-D-galactoside3-O-β-D-galactopyranosyl-quercetinhyperasidhyperozideactoside
02

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)TLR4 (Toll-like receptor 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)AMPK/mTOR axis (AMPK / mTOR signaling axis)

Beyond the preview

Go deeper on hyperoside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyperoside.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call